Loading…
Photolytic and Oxidative Degradation Behavior of Anticancer Drug Venetoclax: Characterization of New Degradation Products Using High Resolution Mass Spectrometry
Venetoclax ( VEN ), an anticancer drug, was subjected to photolytic and oxidative degradation studies. The comprehensive degradation profiling of VEN in both conditions was reported. All the degradation products ( DPs ) were separated on reversed phase HPLC by employing an X-Bridge C18 column with a...
Saved in:
Published in: | Journal of analytical chemistry (New York, N.Y.) N.Y.), 2023-04, Vol.78 (4), p.522-534 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Venetoclax (
VEN
), an anticancer drug, was subjected to photolytic and oxidative degradation studies. The comprehensive degradation profiling of VEN in both conditions was reported. All the degradation products (
DPs
) were separated on reversed phase HPLC by employing an X-Bridge C18 column with ammonium acetate (pH adjusted to 3.20 with acetic acid) and organic solvent mixture of methanol with acetonitrile in the ratio of 90 : 10 as mobile phase. The overall results showed that it underwent significant degradation upon exposure to light (acidic pH) and oxidative (H
2
O
2
at room temperature and 2,2-azobisisobutyronitrile at 40°C) conditions. A total of fifteen new DPs were identified with high resolution mass spectrometry data generated from liquid chromatography–high resolution mass spectrometry system. This information was used for the establishment of a complete degradation pathway of VEN. Additionally, in silico properties,
viz
., absorption, distribution, metabolism, excretion and toxicity (
ADMET
), of VEN and its DPs were predicted with admetSAR software. |
---|---|
ISSN: | 1061-9348 1608-3199 |
DOI: | 10.1134/S1061934823040081 |